Genzyme receives approval to market Elaprase in Japan

Elaprase is an enzyme replacement therapy developed by Shire Human Genetic Therapies. Genzyme is commercializing the product in Japan and other Asia Pacific countries under an agreement with Shire.

Hunter syndrome, also known as mucopolysaccharidosis II (MPS II), is a rare, life-threatening genetic condition mainly affecting males that results from the absence or insufficient levels of the lysosomal enzyme iduronate-2-sulfatase. Without this enzyme, cellular waste products accumulate in tissues and organs which then begin to malfunction, leading to severe clinical complications and early mortality.

David Meeker, president of Genzyme’s lysosomal storage disorders business unit, said: “Our deep experience in Japan in the area of lysosomal storage disorders will enable us to make Elaprase available to all patients who need treatment as quickly as possible. We anticipate that Elaprase will become an increasingly significant contributor for us as we introduce the product across the region.”